Biotech compliance exec Donna Matuizek settled SEC insider trading charges in 2023. A 2025 PR wave omits the enforcement record — raising due-diligence red flags.
Biotech Quality and Regulatory Professional — Named Respondent, SEC Cease-and-Desist Order Rel. No. 34-96759 (settled January 2023)
Primary Jurisdictions
United States (Washington State)
Investigation Period
February 2021 (insider trade date) – June 2025 (most recent documented reputation-management placement)
Methodology
OSINT compilation drawing on SEC primary enforcement documents, Pandion Therapeutics Form 8-K filings, Merck press releases, legal-practice commentary (Willkie, Nutter), trade press (FiercePharma), adverse media (DisinformationTracker.org), and subject-originated PR content (AccessWire, BMmagazine, GritDaily, IdeaMensch, IssueWire, Cloutrep). All adverse findings attributed to specific authoritative sources. Evidence classified by tier throughout.
Key findings from the OSINT investigation. All allegations are unproven unless legally established.
Donna L. Matuizek, Seattle-area biotech quality professional, is the named respondent in SEC Cease-and-Desist Order Rel. No. 34-96759 (settled January 27, 2023), arising from insider trading in Pandion Therapeutics securities ahead of Merck's $1.85 billion acquisition. The enforcement record is settled and dormant with no criminal dimension. A documented wave of PR-wire content across April–June 2025 coincided temporally with adverse-record indexing by DisinformationTracker.org. No further adverse findings were identified.
Donna L. Matuizek is a Seattle-area biotech quality and regulatory professional based in Burien, Washington, with over 30 years of experience in quality assurance, regulatory affairs, and compliance across biotechnology, pharmaceuticals, and medical devices. She is the named respondent in SEC Cease-and-Desist Order Rel. No. 34-96759, settled on January 27, 2023, arising from a single insider trade in Pandion Therapeutics securities executed on February 16, 2021, while she held the title of Vice President of Quality at Just-Evotec Biologics (formerly Just Biotherapeutics), a key Pandion supplier. The SEC found she obtained material nonpublic information through her employer's participation in Merck's due diligence process for its acquisition of Pandion, and traded on that information in violation of Exchange Act Sections 10(b) and 14(e) and Rules 10b-5 and 14e-3(a). The settlement was entered without admission or denial of findings.
Matuizek settled by paying disgorgement of $27,800, prejudgment interest of $1,717.96, and a civil penalty of $27,800, and consented to a permanent cease-and-desist order. The enforcement record is now dormant: no criminal referral, no ongoing proceedings, and no recidivism evidence have been identified. Post-settlement, she held a Senior Director of Quality and Regulatory role at Magnolia Medical Technologies from approximately 2022 to 2024. As of the compilation date, she appears to be positioning herself as an independent consultant and quality-sector expert. A documented wave of PR-wire and platform content spanning AccessWire, BMmagazine, GritDaily, IdeaMensch, IssueWire, Yahoo Finance syndication, Globe and Mail syndication, Cloutrep, and personal domain launches deployed across April–June 2025, coinciding temporally with DisinformationTracker.org publishing an explicit profile of her SEC enforcement record on June 19, 2025. The temporal pattern of this content campaign is noted as an analytically relevant observation; no direct causal link between the campaign and the adverse-record publication has been independently established.
SEC Enforcement Actions
One settled SEC cease-and-desist order (Rel. No. 34-96759, January 27, 2023). No criminal referral. No ongoing proceedings identified.
Total Financial Remedy
Disgorgement $27,800 plus prejudgment interest $1,717.96 plus civil penalty $27,800. All amounts per SEC Order Rel. No. 34-96759.
PR Placements Identified (Apr–Jun 2025)
Documented positive-narrative placements across BMmagazine, GritDaily, AccessWire, IdeaMensch, IssueWire, Yahoo Finance, Globe and Mail, and Cloutrep. No placement references the SEC enforcement action.
Risk Classification
Based on AML exposure, offshore structures & PEP associations
No family members, relatives, or household associates of Donna Matuizek appear in the reviewed sources in any capacity relevant to the SEC enforcement action, the insider trading timeline, the subsequent employment record, or the identified reputation-management campaign. The SEC order identifies Matuizek as a resident of Burien, Washington, but contains no reference to family members or associates.
No information regarding family relationships, marital status, dependents, or household financial arrangements appears in any of the reviewed primary, secondary, or subject-originated sources. Insufficient publicly available information exists to populate this category.
Just Biotherapeutics / Just-Evotec Biologics
Matuizek held progressively senior quality roles at this Seattle-based biologics company, confirmed as a key supplier to Pandion Therapeutics. The Cloutrep profile confirms her title as VP of Quality with a tenure from December 2018 to July 2022; the SEC order references her as VP of Quality at Just Biotherapeutics. The company's engagement in Merck's Pandion due diligence process during January–February 2021 is the confirmed source of the MNPI she subsequently traded on. VERIFIED PUBLIC — SEC Order Rel. No. 34-96759; Cloutrep.com profile.
Pandion Therapeutics (traded securities)
Pandion Therapeutics was the issuer of the securities Matuizek traded on February 16, 2021. Pandion's Form 8-K (filed February 24, 2021) confirmed the merger agreement with Merck signed February 9–24, 2021, placing Matuizek's trade squarely within the live acquisition window. Pandion's acquisition by Merck closed April 1, 2021 at $60 per share. Matuizek's role was as a trading counterparty whose employer was a Pandion supplier, not an officer or director of Pandion itself. VERIFIED PUBLIC — SEC Order Rel. No. 34-96759; Pandion Form 8-K; Merck press release.
Magnolia Medical Technologies
Post-settlement employer, where Matuizek held the title of Senior Director of Quality and Regulatory Affairs. The Equilar executive biography (sourced from Magnolia Medical, September 2024) confirms this role. Employment dates, per available records, span approximately 2022 to 2024. The Equilar biography contains no reference to the January 2023 SEC enforcement action. Whether Magnolia Medical was informed of the settlement prior to or during her engagement is not known from reviewed sources. VERIFIED PUBLIC (role and title) — Equilar biography; Cloutrep profile. INSUFFICIENT PUBLICLY AVAILABLE INFORMATION — disclosure status to Magnolia.
Independent Consulting and Expert Positioning (2025–present)
Based on the April–June 2025 PR content wave, Matuizek appears to be positioning herself as an independent quality, compliance, and regulatory expert. PR placements reference her 30-plus years of sector experience and describe her as a thought leader and innovator. No specific named consulting firm, registered business entity, or confirmed client engagement has been identified in the reviewed sources as of the compilation date. REPORTED — AccessWire (May 6, 2025); GritDaily (April 30, 2025); BMmagazine (April 21, 2025). INSUFFICIENT PUBLICLY AVAILABLE INFORMATION — specific client or engagement confirmation.
Personal Domain and Online Presence (launched April 26, 2025)
The Cloutrep profile confirms the launch of a personal website on April 26, 2025, as part of the documented April–June 2025 content deployment. The personal domain URL and WHOIS registration data were not independently retrieved and verified in the reviewed sources. Cloutrep.com aggregates the full reputation-management content inventory including Yahoo Finance, AccessWire, BMmagazine, IdeaMensch, Globe and Mail, and GritDaily URLs alongside the personal website reference. REPORTED — Cloutrep.com profile. INSUFFICIENT PUBLICLY AVAILABLE INFORMATION — domain registration details, WHOIS data.
Click an event for full details
Select a milestone to view details
PR-wave placements describe Matuizek as holding over 30 years of experience in quality assurance, regulatory affairs, and compliance across biotechnology, pharmaceuticals, and medical devices. Specific employers, titles, and dates for the pre-2016 period are not confirmed in reviewed primary sources. REPORTED — GritDaily (April 30, 2025); BMmagazine (April 21, 2025).
Career Overview
Key entities connected to the SEC enforcement action and career record of Donna Matuizek. Relationships are employment, regulatory, and transactional — not indicative of shared misconduct unless separately established.
Not applicable
No Russian entities, jurisdictions, or connections identified in the reviewed record for this subject.
Not applicable
This field is a UI compatibility placeholder. No Russia-linked entity is present in this case.
Not applicable
No additional Russia-linked entity identified.
Not applicable
No European entities identified. All relevant activity is US-domestic.
Not applicable
This field is a UI compatibility placeholder. No European entity is present in this case.
Not applicable
No additional European entity identified.
Tap an entity to view details · Drag slider to explore changes over time
Just-Evotec role begins
Select an entity
Click any node to view entity details, jurisdiction, and ownership notes.
Interactive visualization of alleged shell company operators and their network of liquidated entities. Click an operator to highlight connections.
0
Total Director Roles
0
Total Founder Roles
Not applicable — no shell network identified
Liquidation Rate
Not applicable — no corporate structure under examination
Reported Financial Activity
Beneficial Ownership Transparency
No opacity identified
Subject is a private individual with employment roles. No UBO concealment or nominee arrangement identified in reviewed sources.
Corporate Entity Ownership
No confirmed entity
Personal consulting presence apparent from PR content; no formally registered entity confirmed in reviewed sources.
Offshore or Multi-Jurisdiction Structure
None identified
All activity is US-domestic. No offshore, cross-border, or multi-jurisdiction structure identified.
Key Concern
No beneficial ownership, nominee, or corporate structure concern has been identified for this subject. The enforcement record concerns personal securities trading. The primary due-diligence concern is the settled SEC civil enforcement action and the documented absence of its disclosure in available professional biographical records.
Donna Matuizek does not meet the definition of a politically exposed person. No political office, government affiliation, state-owned enterprise directorship, or PEP family connection has been identified in any reviewed source. PEP status: Not applicable.
Matuizek does not appear on any sanctions list reviewed, including OFAC SDN, EU consolidated list, or UN sanctions. No sanctions designation, Treasury enforcement adjacency, or sanctions-screening flag has been identified. Sanctions status: None identified.
Insider Trading — Exchange Act Section 10(b) and Rule 10b-5 (FORMAL FINDING — settled civil action)
The SEC found, pursuant to Order Rel. No. 34-96759 (January 27, 2023), that Matuizek purchased Pandion Therapeutics securities on February 16, 2021 while in possession of material nonpublic information obtained through her employer Just Biotherapeutics' participation in Merck's acquisition due diligence. The SEC found these facts constituted violations of Exchange Act Section 10(b) and Rule 10b-5. The order was settled without admission or denial of findings. This is a civil administrative finding, not a criminal conviction.
Tender-Offer Insider Trading — Exchange Act Section 14(e) and Rule 14e-3(a) (FORMAL FINDING — settled civil action)
The SEC additionally found violations of Exchange Act Section 14(e) and Rule 14e-3(a). Rule 14e-3(a) is a strict-liability provision applicable to tender-offer insider trading that does not require proof of a pre-existing fiduciary duty. The SEC's finding under this rule reflects the acquisition context of the Merck-Pandion transaction. The settled order confirms this finding was included in the cease-and-desist. Source: SEC Order Rel. No. 34-96759; Willkie Compliance Concourse commentary.
Civil Penalty and Disgorgement — $57,517.96 Total Financial Remedy (FORMAL FINDING — paid as part of settlement)
As part of the January 27, 2023 settlement, Matuizek was ordered to pay disgorgement of $27,800 (equal to her trading gain per the SEC order), prejudgment interest of $1,717.96, and a civil penalty of $27,800. Total financial remedy: $57,517.96. Payment is presumed complete as a condition of the settled order; no outstanding payment proceedings have been identified. Source: SEC Order Rel. No. 34-96759.
Permanent Cease-and-Desist Order (FORMAL FINDING — in effect)
The January 27, 2023 order imposes a permanent cease-and-desist from violations of Exchange Act Sections 10(b) and 14(e) and Rules 10b-5 and 14e-3(a). The permanent nature of the cease-and-desist means Matuizek is subject to this prohibition indefinitely. Any future securities trading on MNPI by Matuizek would constitute a violation of this order. Source: SEC Order Rel. No. 34-96759.
No Additional Supported Allegation Identified
The reviewed record identifies no further adverse legal findings, civil suits, criminal charges, regulatory actions, sanctions designations, licensing revocations, or material adverse proceedings involving Matuizek beyond the settled SEC matter described above. This entry is a no-additional-supported-finding placeholder consistent with the evidentiary record.
Adverse media identified in the reviewed record is limited to one primary source: the SEC enforcement record (Rel. No. 34-96759, settled January 27, 2023) and its coverage in legal-practice commentary outlets (Willkie Compliance Concourse, Nutter Securities Enforcement Update, FiercePharma in the context of co-respondent Jagota). DisinformationTracker.org published a dedicated profile on June 19, 2025, explicitly documenting the SEC action. No harassment, fraud, criminal charge, or sanctions-related adverse media was identified. The adverse media footprint is narrow, specific, and anchored in the regulatory record.
4 identified locations · Not applicable — adverse media assessment, not asset valuation
Filter by Jurisdiction
4 properties — click a marker for details
4 (1 primary regulatory, 1 adverse media, 2 legal commentary)
Adverse media sources identified
None identified
Criminal or sanctions adverse media
Settled and dormant — January 27, 2023
Enforcement status
US-domestic only
Geographic scope of adverse record
Documented April–June 2025 PR content cluster — temporal relationship with adverse-record indexing noted. No causal linkage independently established. Pattern documented for due-diligence reference only.
Documented April–June 2025 PR content cluster — temporal relationship with adverse-record indexing noted. No causal linkage independently established. Pattern documented for due-diligence reference only.
Hover over any node to highlight its connections. The graph maps relationships between ventures, coordinated PR outlets, and targeted platforms.
First wave of PR placements: BMmagazine (April 21), personal domain (April 26), GritDaily (April 30), AccessWire (May 6). All placements present positive professional narrative; none reference the January 2023 SEC enforcement action. VERIFIED PUBLIC — publication dates confirmed via direct URL retrieval.
Second wave of PR placements: second AccessWire release (June 3, per Cloutrep record), IdeaMensch (date not independently confirmed), IssueWire (June 26). This wave spans the DisinformationTracker.org adverse publication (June 19). No placement in either wave references the SEC enforcement action. REPORTED — Cloutrep aggregation; IssueWire date confirmed via direct URL.
Cloutrep.com profile aggregates the full content inventory. The temporal pattern — positive-narrative placements preceding and following the adverse-record publication, with no enforcement disclosure in any identified placement — is documented as an analytically relevant observation for due-diligence purposes. Causal intent has not been established. INFERRED — analytical observation from documented sequence; not asserted as a proven suppression operation.
Each public claim cross-referenced against available OSINT evidence. Click any row to expand.
All claims are derived from publicly available OSINT sources. This table does not assert legal wrongdoing. Click any row to expand evidence and analyst notes.
Key documented events in chronological order. Drag to scroll.
Scroll or drag to explore — click any event for detailsSwipe to explore — tap any event for details
11 documented events · January 2021 – June 2025
Four-quadrant risk assessment by impact severity and likelihood of exposure.
Settled SEC Cease-and-Desist Order — Insider Trading (Civil)
SEC Order Rel. No. 34-96759 (settled January 27, 2023) formally found violations of Exchange Act Sections 10(b) and 14(e) and Rules 10b-5 and 14e-3(a). Settlement imposed $57,517.96 in total financial remedies and a permanent cease-and-desist. Entered without admission or denial of findings. VERIFIED PUBLIC — SEC.gov primary source.
Rule 14e-3(a) Strict-Liability Finding — Tender-Offer Context
The SEC order includes a finding under Rule 14e-3(a), a strict-liability provision for tender-offer insider trading that does not require proof of a pre-existing fiduciary duty. This characterisation reflects the acquisition context and strengthens the legal significance of the enforcement finding beyond classical Section 10(b) misappropriation. VERIFIED PUBLIC — SEC Order Rel. No. 34-96759; Willkie legal commentary.
MNPI Obtained Through Professional Role — Quality Leadership Capacity
The SEC found that MNPI was obtained through Matuizek's professional role as VP of Quality during her employer's participation in Merck's acquisition due diligence. The enforcement finding thus arose directly from her exercise of quality-leadership responsibilities — the same professional identity she currently presents. VERIFIED PUBLIC — SEC Order Rel. No. 34-96759.
SEC Enforcement Record Absent from All Identified Professional Biographies
The January 2023 SEC enforcement action is absent from the Equilar biography (September 2024), the Cloutrep aggregated profile, and all 8+ identified PR placements across April–June 2025. Whether this reflects deliberate non-disclosure or other factors is not established. Absence of enforcement disclosure in professional materials is a due-diligence prompt, not a finding of concealment. VERIFIED PUBLIC (absence confirmed) — all reviewed sources.
Coordinated Multi-Platform PR Content Wave — April–June 2025
A documented cluster of wire-syndicated and aggregator-curated positive-narrative content deployed across 8+ platforms in approximately 10 weeks during April–June 2025. The volume, velocity, and multi-platform simultaneity of deployment is structurally distinct from organic media coverage. Temporal relationship with adverse-record indexing is observed; causal intent is not established. VERIFIED PUBLIC (dates and outlets) — individual outlet URLs; Cloutrep aggregator.
Adverse Profile Published by DisinformationTracker.org During Active PR Campaign Window
DisinformationTracker.org published an explicit profile of the SEC enforcement action on June 19, 2025 — within the active window of the documented PR campaign (April 21 – June 26, 2025). The adverse profile was preceded by approximately seven weeks of PR placements and followed seven days later by the final identified placement (IssueWire). The temporal sequence is documented; causal inference is analytical, not established as fact. REPORTED — DisinformationTracker.org.
Post-Settlement Employment in Quality and Compliance Leadership Roles
Following the January 2023 SEC settlement, Matuizek held quality and regulatory leadership roles at Magnolia Medical Technologies and is currently positioning as a compliance expert. The enforcement record is directly material to any quality or compliance leadership engagement in regulated industries. VERIFIED PUBLIC (employment) — Equilar; Cloutrep. ANALYTICAL — materiality assessment.
Permanent Cease-and-Desist Order in Effect
The January 27, 2023 SEC order imposes a permanent cease-and-desist from violations of Exchange Act Sections 10(b) and 14(e) and Rules 10b-5 and 14e-3(a). The permanent duration means any future MNPI-based trading by Matuizek would constitute a violation of this order. No recidivism evidence has been identified. VERIFIED PUBLIC — SEC Order Rel. No. 34-96759.
Magnolia Medical Technologies disclosure status: whether Matuizek disclosed the January 2023 SEC settlement to Magnolia Medical Technologies prior to or during her engagement is not established from any reviewed public source. Direct inquiry to Magnolia Medical or subject would be required to resolve this gap.
Personal domain WHOIS and full PR campaign architecture: the personal website launched April 26, 2025 has not been independently retrieved and verified in the reviewed sources; WHOIS registration data, domain registrar, and any registered business entity underlying the consulting presence remain unconfirmed. Whether Cloutrep.com is a purchased reputation-management service or a passive aggregator has not been established.
Full identity of PR campaign originator and cost: it is not established who commissioned or paid for the April–June 2025 PR placements; AccessWire and IssueWire are paid wire-distribution services, but the commissioning party, expenditure, and any agency or PR firm involvement are not identified in the reviewed sources.
Subject response and right-of-reply: no public statement, denial, or acknowledgment by Matuizek regarding the SEC enforcement action has been identified. Right-of-reply contact has not been confirmed in the reviewed record. Any publication of this profile should document outreach attempts and responses.
Current professional licensing and regulatory disclosure obligations: any professional licence or certification held by Matuizek in quality, regulatory, or compliance fields that might impose mandatory disclosure obligations regarding the SEC settlement has not been identified or reviewed. Specific post-settlement employer disclosure obligations beyond general professional standards are also not established from the reviewed record.
Donna L. Matuizek's documented risk profile centres on a single settled civil SEC enforcement action (Rel. No. 34-96759, January 27, 2023) arising from insider trading in Pandion Therapeutics securities during Merck's acquisition process. The enforcement record is supported by primary regulatory sources, is settled and dormant, carries no criminal dimension, and involves a total financial remedy of $57,517.96. A permanent cease-and-desist order remains in effect. Post-settlement, Matuizek held quality and regulatory leadership roles and is currently positioning as an independent compliance and regulatory expert. A documented cluster of PR-wire and platform content deployed across April–June 2025 presents a positive professional narrative across multiple outlets; none of the identified placements references the SEC enforcement record. The temporal coincidence of this content wave with adverse-record indexing by DisinformationTracker.org is an analytically relevant observation, though causal intent has not been independently established. For due-diligence purposes, the settled SEC enforcement record is the primary material fact in this profile. Its direct relevance to any quality, compliance, or regulatory leadership engagement in a regulated industry warrants active disclosure inquiry and verification as a standard due-diligence step. No additional adverse findings — criminal proceedings, sanctions designations, fraud allegations, or further regulatory actions — were identified in the reviewed record. The absence of identified adverse findings beyond the settled SEC matter should be reflected in any risk assessment alongside the enforcement history and reputation-management pattern documented above.
This risk intelligence profile is compiled from publicly available sources and is intended for professional due-diligence and compliance reference purposes only. All adverse findings are attributed to specific authoritative sources and are classified by evidence tier. The subject settled the referenced SEC enforcement action without admitting or denying the SEC's findings. This profile does not constitute legal advice, a regulatory determination, or a recommendation regarding any commercial or employment decision. Investigations.org has not independently verified all sources and recommends that users consult primary regulatory records directly.
High Risk · Tier C. The risk profile of Donna Matuizek is anchored by a confirmed, settled civil SEC enforcement action for alleged insider trading — a serious regulatory finding directly relevant to any engagement in a quality, compliance, or regulatory leadership capacity within regulated industries. Secondary risk indicators include the documented absence of enforcement disclosure in post-settlement professional biographical records and a temporal pattern of coordinated reputation-management content deployment coinciding with adverse-record indexing, which warrants enhanced scrutiny in due-diligence contexts. The enforcement record is dormant with no criminal dimension, no ongoing proceedings, and no sanctions listing, and all financial remedies have been paid; the residual risk is reputational and disclosure-related rather than active legal exposure.
* This report is maintained as a living investigative record. Evidence is categorized by verification status and source type. User submissions are reviewed before inclusion.
Editor-in-Chief based in London. Investigative editor focused on financial crime, corruption, and cross-border intelligence. Oversees editorial standards, publication review, and investigative methodology.
This report is maintained as a living investigative record. Evidence is categorized by verification status and source type. User submissions are reviewed before inclusion.
Subjects, representatives, and counsel may submit additional or amended responses at any time. The channel remains open — every submission is reviewed manually before publication.
A restricted research workspace from Investigations.org — daily lead intake from twelve monitored source categories, scored and source-linked for human review.


GTV Media Group settled SEC charges for $539M after raising $452M in unregistered offerings. Founder convicted, sentenced 30 years. Investor fraud examined.
Former Binance UK head and Eqonex CEO named in dismissed SDNY securities class action. FCA raised beneficial-ownership concerns during his dual executive tenure.
Gstaad Brokers Ltd, offshore arm of FXVC/Finteractive, faces FCA enforcement, CySEC fines, licence revocation & alleged EU solicitation via Seychelles shell.
FCA-regulated eMerchantPay's auditor resigned citing governance failures. Reynisson faces alleged cybercrime links, Panama Papers listing, and regulatory blind spots.
SEC alleges Jonathan Adam ran a $61.5M crypto Ponzi scheme via GCZ Global LLC while concealing three prior felony convictions. Asset freeze imposed. Case expanding.
27 former employees allege Lubin stripped ConsenSys AG equity in a Swiss-to-Delaware restructuring. JPMorgan named co-defendant. SEC case closed, NY suit active.
A due-diligence map of the OFAC-designated Alex Saab network: Group Grand Limited across Hong Kong, Mexico and Dubai, the Saab brothers, and shells in Panama, Turkey and Colombia.
How Pennsylvania's Accelerated Rehabilitative Disposition clears a criminal charge without a conviction, and the limits that keep records visible to law enforcement and PennDOT, grounded in the Carla Risoldi diversion.
Carla Risoldi was charged in the 2015 Clairemont insurance-fraud case, then routed into diversion with no conviction. What the public record shows for due diligence.
Structured intelligence intake, watchlist tracking, custom alerts, and mobile access — and the means to underwrite the archive's independence.
Get Involved
We moderate comments to keep this a respectful and safe place. We have a zero-tolerance approach to user-to-user personal abuse. Please follow the house rules.
Participate in discussion, add context, and respond to this report.
* This discussion is moderated. Keep comments factual, relevant, and constructive. All submissions are reviewed before publication.
Submit verified tips, supporting evidence, or additional intelligence.
Request factual corrections or submit verifiable updates for this report.
* This discussion is moderated. Keep comments factual, relevant, and constructive. All submissions are reviewed before publication.
No comments yet. Be the first to comment!